WO2007009730A8 - Polymerfilm für transdermale pflaster mit pharmazeutischem wirkstoff - Google Patents

Polymerfilm für transdermale pflaster mit pharmazeutischem wirkstoff

Info

Publication number
WO2007009730A8
WO2007009730A8 PCT/EP2006/007021 EP2006007021W WO2007009730A8 WO 2007009730 A8 WO2007009730 A8 WO 2007009730A8 EP 2006007021 W EP2006007021 W EP 2006007021W WO 2007009730 A8 WO2007009730 A8 WO 2007009730A8
Authority
WO
WIPO (PCT)
Prior art keywords
polymer film
pharmaceutical active
transdermal patches
active agent
patches containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/007021
Other languages
English (en)
French (fr)
Other versions
WO2007009730A2 (de
WO2007009730A3 (de
WO2007009730B1 (de
Inventor
Stefan Bracht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to EP06762658A priority Critical patent/EP1906942A2/de
Priority to JP2008521866A priority patent/JP2009501743A/ja
Priority to CA002614097A priority patent/CA2614097A1/en
Publication of WO2007009730A2 publication Critical patent/WO2007009730A2/de
Publication of WO2007009730A8 publication Critical patent/WO2007009730A8/de
Publication of WO2007009730A3 publication Critical patent/WO2007009730A3/de
Publication of WO2007009730B1 publication Critical patent/WO2007009730B1/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
    • B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
    • B09B3/00—Destroying solid waste or transforming solid waste into something useful or harmless
    • B09B3/70—Chemical treatment, e.g. pH adjustment or oxidation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
    • B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
    • B09B2101/00—Type of solid waste
    • B09B2101/65—Medical waste
    • B09B2101/68—Transdermal patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental & Geological Engineering (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Die Erfindung betrifft einen Polymerfilm für transdermale Pflaster mit pharmazeutischem Wirkstoff, wobei der Polymerfilm eine oder mehrere Schichten mit einem Gehalt an mindestens einem Zersetzungsbeschleuniger für pharmazeutische Wirkstoffe enthält. Der erfindungsgemäße Polymerfilm ist im erfinderischen Verbund mit transdermalen Pflastern, welche pharmazeutische Wirkstoffe aus der Gruppe der Gestagene, der Estrogene oder Androgene enthalten können zur umweltschonenden Entsorgung dieser Pflaster, beispielsweise Pflaster zur Hormonersatztherapie und zur Fertilitätskontrolle einsetzbar.
PCT/EP2006/007021 2005-07-18 2006-07-17 Polymerfilm für transdermale pflaster mit pharmazeutischem wirkstoff Ceased WO2007009730A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06762658A EP1906942A2 (de) 2005-07-18 2006-07-17 Polymerfim für transdermale pflaster mit pharmazeutischem wirkstoff
JP2008521866A JP2009501743A (ja) 2005-07-18 2006-07-17 医薬活性剤を含む経皮用パッチのためのポリマーフィルム
CA002614097A CA2614097A1 (en) 2005-07-18 2006-07-17 Polymer film for transdermal patches with pharmaceutical active

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70011605P 2005-07-18 2005-07-18
US60/700,116 2005-07-18

Publications (4)

Publication Number Publication Date
WO2007009730A2 WO2007009730A2 (de) 2007-01-25
WO2007009730A8 true WO2007009730A8 (de) 2007-05-24
WO2007009730A3 WO2007009730A3 (de) 2007-09-07
WO2007009730B1 WO2007009730B1 (de) 2007-10-25

Family

ID=37669161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/007021 Ceased WO2007009730A2 (de) 2005-07-18 2006-07-17 Polymerfilm für transdermale pflaster mit pharmazeutischem wirkstoff

Country Status (5)

Country Link
US (1) US20070014839A1 (de)
EP (1) EP1906942A2 (de)
JP (2) JP2009501743A (de)
CA (1) CA2614097A1 (de)
WO (1) WO2007009730A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006025282A1 (de) * 2006-05-31 2007-12-20 Lts Lohmann Therapie-Systeme Ag Selbstzerstörendes transdermales therapeutisches System
US20080286348A1 (en) * 2007-05-16 2008-11-20 Todhunter John A Secured transdermal delivery system
US7883487B2 (en) * 2008-06-16 2011-02-08 Shantha Totada R Transdermal local anesthetic patch with injection port
DE102009036485B4 (de) * 2009-08-07 2012-10-04 Lts Lohmann Therapie-Systeme Ag Mittel zur zerstörenden Entsorgung von medizinischen Wirkstoffen in transdermalen therapeutischen Systemen
CN101942368B (zh) * 2010-09-25 2011-12-07 杜井民 羊毛脱黄去污剂
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10398733B2 (en) 2013-03-15 2019-09-03 Cda Research Group, Inc. Topical copper ion treatments and methods of treatment using topical copper ion treatments in the dermatological areas of the body
US11318089B2 (en) * 2013-03-15 2022-05-03 Cda Research Group, Inc. Topical copper ion treatments and methods of making topical copper ion treatments for use in various anatomical areas of the body
US11007143B2 (en) 2013-03-15 2021-05-18 Cda Research Group, Inc. Topical copper ion treatments and methods of treatment using topical copper ion treatments in the oral-respiratory-otic areas of the body
US11000545B2 (en) 2013-03-15 2021-05-11 Cda Research Group, Inc. Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza
US11083750B2 (en) 2013-03-15 2021-08-10 Cda Research Group, Inc. Methods of treatment using topical copper ion formulations
US12318406B2 (en) 2013-03-15 2025-06-03 Cda Research Group, Inc. Methods of treatment using topical copper ion formulations
EP3145489A1 (de) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natürliche kombinierte hormonersatzformulierungen und therapien
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017094709A1 (ja) * 2015-12-01 2017-06-08 株式会社リコー 水崩壊性樹脂組成物及びこれを用いた三次元造形用材料セット並びに三次元造形物の製造方法
WO2017104415A1 (ja) * 2015-12-18 2017-06-22 株式会社リコー 水崩壊性複合材料、及び立体造形物の製造方法
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10668312B2 (en) 2018-10-03 2020-06-02 Okra Medical, Inc. Controlled medication denaturing composition
US11193184B2 (en) 2019-02-22 2021-12-07 Cda Research Group, Inc. System for use in producing a metal ion suspension and process of using same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178361A (en) * 1973-09-10 1979-12-11 Union Corporation Sustained release pharmaceutical composition
US5047249A (en) * 1988-07-22 1991-09-10 John Morris Co., Inc. Compositions and methods for treating skin conditions and promoting wound healing
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5804215A (en) * 1997-03-21 1998-09-08 L. Perrigo Company Transdermal patch disposal system and method
US5948433A (en) * 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6689344B2 (en) * 2000-03-17 2004-02-10 Lg Household & Healthcare Ltd. Patches for teeth whitening
US6419906B1 (en) * 2001-03-12 2002-07-16 Colgate Palmolive Company Strip for whitening tooth surfaces
DK2062573T3 (da) * 2001-05-01 2012-01-30 Euro Celtique Sa Misbrugsresistent opioid indeholdende transdermale systemer
ES2283812T3 (es) * 2002-06-10 2007-11-01 Euro Celtique Sa Sistemas de eliminacion de dispositivos de adminsitracion transdemica para prevenir el uso indebido de los agentes activos contenidos en los mismos.
US20050112068A1 (en) * 2003-10-28 2005-05-26 Warner Kevin S. Systems and methods for reducing unintended use of active ingredients in dermal delivery devices
GB0401113D0 (en) * 2004-01-19 2004-02-18 Glaxo Group Ltd Tooth whitening composition

Also Published As

Publication number Publication date
WO2007009730A2 (de) 2007-01-25
JP2009501743A (ja) 2009-01-22
JP2013064012A (ja) 2013-04-11
WO2007009730A3 (de) 2007-09-07
WO2007009730B1 (de) 2007-10-25
EP1906942A2 (de) 2008-04-09
US20070014839A1 (en) 2007-01-18
CA2614097A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
WO2007009730A3 (de) Polymerfilm für transdermale pflaster mit pharmazeutischem wirkstoff
WO2005070003A3 (en) Abuse potential reduction in abusable substance dosage form
Balthazart et al. Preoptic aromatase modulates male sexual behavior: slow and fast mechanisms of action
WO2005002482A8 (en) Transdermal hormone delivery system: compositions and methods
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
DK1089722T3 (da) Transdermalt plaster af matrixtypen til steroidhormoner
WO2007084314A3 (en) MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
AR082998A1 (es) Asociacion farmaceutica para tratar y/o prevenir mioma y/o endometriosis, uso de resveratrol y progestogeno, composicion farmaceutica para tratamiento y/o prevencion de mioma y/o endometriosis, medicamento para tratamiento y/o prevencion de mioma y/o endometriosis, kit y metodo para tratamiento y/o prevencion de mioma y/o endometriosis
BR0209872A (pt) Método e composição para desvulcanização de refugo de borracha
WO2009052171A3 (en) Controlled release remediation system and composition
ATE275393T1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
CR8800A (es) Regimenes y equipos anticonceptivos de antagonistas del receptor de progesterona
PL353738A1 (en) Composition containing an active substance, production and use thereof
WO2005077968A8 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
GB0404586D0 (en) Improvements in or relating to organic materials
WO2002030477A8 (en) Use of n-halamine biocidal polymer for odor control
MXPA06010767A (es) Composicion farmaceutica anhidra que asocia un agente siliconado y principio activo solubilizado.
GEP20115210B (en) Antimicrobial agent
WO2005041883A3 (en) Reduction of unintended use of transdermal devices
WO2004091535A3 (en) Methods of administering estrogens and progestins
KR970701538A (ko) 데소게스트렐 함유 경피 투여제(desogestrel-containing transdermal vapplication agent)
BRPI0417530B8 (pt) composição para a liberação transdérmica de hormônios sem a necessidade de melhoradores de penetração, sistema terapêutico transdérmico, e kit
WO2008092500A8 (en) Method and device for safe storage and delivery of ammonia and use of storage materials
ATE282408T1 (de) Periadventitiales verabreichungssystem

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006762658

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2614097

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008521866

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06762658

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2006762658

Country of ref document: EP